Abstract 288P
Background
The family planning program curated by the Indonesian government to limit population growth has been successful. Hormonal contraception contains progesterone and estrogen, risk factors for breast cancer. Breast cancer is a prominent health issue in Indonesia as it has a high incidence rate and accounts for the second-highest mortality in women. the purpose of this research, looking at how the effect of hormonal contraceptives on estradiol and progesterone levels in breast cancer patients.
Methods
a six-year prospective cohort study at Dr. Moewardi Hospital. There are two groups of subjects with and without hormonal contraceptives. Data on breast cancer stage, tumor characteristics, estradiol levels, and progesterone levels were collected. The data are presented in mean, standard deviation, and distribution frequency (%). Statistical tests using Chi-square, Fisher exact, Mann-Whitney, and an independent t-test.
Results
303 samples were aged 31 to 78 years. 51% grade III, 28.7% Luminal B, and 45.9% LABC. 54.1% high estradiol levels, and 80.5% normal progesterone levels. The use of contraceptives, the type, duration of use, and duration of discontinuation of contraceptives do not affect estradiol and progesterone levels (p>0.05). Estradiol levels affect PFS, DFS, and OS (p<0.05) while progesterone levels have no effect (p>0.05). The type and duration of contraceptive use do not affect PFS, DFS, and OS (p>0.05). While the duration of discontinuation of contraceptives affects the OS (p<0.05) but not PFS and DFS (p>0.05).
Conclusions
PFS, DFS, and OS in breast cancer are affected by significantly high levels of estradiol, and in contrast, progesterone levels tend to be normal and not significantly affected. Lower levels of estradiol are associated with a better OS. A shorter duration for stopping the use of contraceptives is associated with a worse OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
293P - Generic dabigatran for cancer-associated venous thromboembolism: Real-world data
Presenter: Fen Saj
Session: Poster viewing 04
294P - Cross-sectional analysis on cancer-related distress, belief in alternative medicine among cancer patients and attendants visiting a tertiary care center in Northern India
Presenter: Amit Sehrawat
Session: Poster viewing 04
296P - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Presenter: Yi-Long Wu
Session: Poster viewing 04
297P - Transbronchial microwave ablation of early lung cancers and lung oligometastases: Mid-term results
Presenter: Joyce Chan
Session: Poster viewing 04
298P - Does trisegmentectomy have functional benefit over lobectomy? Comparative analysis of changes in lung function and volumetry among stage IA non-small cell lung cancer patients
Presenter: sumin shin
Session: Poster viewing 04
299P - Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery
Presenter: Qingyi Zhang
Session: Poster viewing 04
300P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Presenter: Xin Shang
Session: Poster viewing 04
301P - Oxygen desaturation during 6-min walk test: Implications for postoperative complications in non-small cell lung cancer patients with impaired lung function
Presenter: Hye Yun Park
Session: Poster viewing 04
302P - Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study
Presenter: Jin-Yuan Shih
Session: Poster viewing 04